论文部分内容阅读
1969年意大利学者Bonadonna首次报道阿霉素(Adriamycyn,AMD)临床应用至今已有20年的历史,此间对该药的药理性能、作用机理、抗癌谱以及毒副反应已有较为深入的研究,尤其在抗癌谱方面发现该药对白血病、淋巴瘤、何杰金氏病、尤文氏肉瘤、横纹肌肉瘤、乳腺癌、小细胞肺癌、卵巢癌、膀胱癌、骨肉瘤、骨癌、肝癌、前列腺癌、甲状腺癌、头颈部癌、生殖器癌均有显著的疗效。本文着重就ADM对胃肠道肿瘤治疗作用予以概述,并讨论其作用机理及其毒副反应。
In 1969, the Italian scholar Bonadonna reported for the first time that the clinical application of Adriamycyn (AMD) has been for 20 years. There have been in-depth studies on the pharmacological properties, mechanism of action, anti-cancer spectrum and toxicity of the drug. The drug was found especially in anti-cancer spectrums for leukemia, lymphoma, Hodgkin’s disease, Ewing’s sarcoma, rhabdomyosarcoma, breast cancer, small cell lung cancer, ovarian cancer, bladder cancer, osteosarcoma, bone cancer, liver cancer, prostate Cancer, thyroid cancer, head and neck cancer, and genital cancer have significant effects. This article focuses on the role of ADM in the treatment of gastrointestinal cancer, and discusses its mechanism of action and its toxic and side effects.